Science of GluteGuard
The Gluten Problem
When gluten is consumed, the body’s pancreatic enzymes (pepsin, trypsin and chymotrypsin) which are found in the gastrointestinal tract are unable to fully digest the gluten proteins. Rather the proteins are only partly broken down, leaving smaller, undigested, sections called ‘peptides’.
Most people are not affected by these peptides. For others with recognised gluten disorders, the peptides can be toxic or capable of triggering an auto-immune reaction, leading to the symptoms and intestinal damage observed in gluten-related disorders.
An Innovative Natural Enzyme
Undigested peptides interact with intestinal lining, causing a cascade of events that leads to symptoms, inflammation and the associated autoimmune response that leads to intestinal damage.
When taken before a meal, GluteGuard’s enteric coating ensures its quick delivery to the duodenum where the enzymes are released. The enzymes target and breakdown the peptides into harmless fragments, which then follow through the normal digestive process without causing symptoms or immune activation.
GluteGuard is the culmination of decades of Australian clinical and scientific research. Early work by Prof. Hugh Cornell illustrating the biochemical composition of gluten, has been instrumental to today’s understanding of gluten’s toxicity in gluten related disorders.
Prof. Hugh Cornell, a former Professor of Biological Chemistry at the RMIT University and Dr. Teodor Stelmasiak a veterinary pathologist with over 25 years of experience in pharmaceutical research, hypothesised that if the right enzyme is delivered to the gastrointestinal tract prior to the consumption of foods, it could complete the digestion of the toxic and immunogenic gluten peptides and protect patients against the effects caused by inadvertent gluten ingestion.
This was followed by the discovery of Caricain, which became the catalyst for the establishment of Glutagen by Dr Stelmasiak in 2001 and the subsequent development of GluteGuard.GluteGuard is a product of decades of Australian scientific research.
GluteGuard was extensively researched in-vitro and in randomised placebo controlled clinical trials exploring the effect of caricain supplementation on symptoms and biomarkers of gluten related conditions. These trials demonstrated that GluteGuard was successful at protecting participants against the effects of a daily gluten challenge .
For healthcare professionals enquiring about GluteGuard’s clinical research please visit